'Amylin is focused on bringing innovative medicines with life-changing therapeutic potential to patients through our sustainable approach to the discovery and development of drugs,' said Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals. 'At this year's R&D Day, we look forward to presenting an update on our opportunities to build near-term value with our marketed products, discussing our recent exciting clinical results from the once-weekly exenatide program and the pramlintide/leptin program, and providing insights into our research strategy.'
The agenda for this year's R&D Day includes presentations by the following officers of Amylin Pharmaceuticals:
-- Introduction
Daniel M. Bradbury
President and Chief Executive Officer
-- Diabetes Programs
Orville Kolterman, MD
Senior Vice President of Clinical and Regulatory Affairs
-- Obesity Programs
Alain Baron, MD
Senior Vice President of Research
-- Discovery Research
Michael Hanley, PhD
Vice President of Discovery Research
A question and answer session will follow the presentations.
The presentation will be webcast live through Amylin's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to http://www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in
SOURCE Amylin Pharmaceuticals, Inc.